Counterpart International – Trademark Portfolio
Entity Type: 03
Counterpart International holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 5 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include COUNTERPART INTERNATIONAL and SOCIAL SECTOR ACCELERATOR. The owner is based in Arlington, VA.
2345 Crystal Drive, Suite 301
Arlington, VA 22202
Showing of trademarks Trademarks
Trademark Classifications
Counterpart International's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Education; providing of training; entertainment; sporting and cultural activities
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does Counterpart International have?
Counterpart International has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 2 cancelled.
What trademark classes does Counterpart International file in?
Counterpart International files trademarks across 2 Nice Classification classes. The most active classes are Class 41 (Education & Entertainment), Class 36 (Insurance & Financial). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.
What are Counterpart International's most well-known trademarks?
Counterpart International's registered trademark portfolio includes well-known marks such as COUNTERPART INTERNATIONAL and SOCIAL SECTOR ACCELERATOR. These are among 2 currently registered trademarks in the portfolio.
What is Counterpart International's trademark registration success rate?
Counterpart International has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.